Veru Inc. and Eli Lilly and Company entered into a clinical trial collaboration and supply agreement to evaluate the efficacy and safety of enobosarm, Veru’s first-in-class, selective androgen receptor targeting agonist, in combination with Lilly’s Verzenio (abemaciclib), a CDK4/6 inhibitor, as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer.
City of Hope launched a national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.
